Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610932 | 0.81 | ALDH1A1 (0.81) | ALDH1A1L3MBTL1PTGDR2MAPTSMN1; SMN2 | |
| SCHEMBL13623674 | 0.75 | ALDH1A1 (0.80) | ALDH1A1L3MBTL1MAPTKMT2ARAB9A | |
| SCHEMBL14048505 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1L3MBTL1TSHRSMN1; SMN2POLB | |
| SCHEMBL7721154 | 0.70 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1MAPTKMT2ATSHR | |
| SCHEMBL18250756 | 0.68 | TSHR (0.49) | ALDH1A1L3MBTL1TSHRSMN1; SMN2CNR1 | |
| SCHEMBL4296199 | 0.68 | L3MBTL1 (0.91) | ALDH1A1L3MBTL1PTGDR2MAPTKMT2A | |
| SCHEMBL20206668 | 0.68 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTKMT2ARAB9A | |
| SCHEMBL18250331 | 0.67 | SMN1; SMN2 (0.51) | ALDH1A1L3MBTL1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5107891 | 0.66 | PTGDR2 (0.49) | PTGDR2TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL7721157 | 0.65 | SMN1; SMN2 (0.47) | ALDH1A1L3MBTL1PTGDR2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | ALDH1A1 2368/4885L3MBTL1 4358/4885PTGDR2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.